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Abstract
Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility
and disease progression. It is not known to what extent this effect is due to a modulation of peripheral lymphocyte function,
or to intrathecal effects of vitamin D. We investigated the effect of dietary vitamin D3 content on de/remyelination in the
cuprizone model, which is a well established toxic model of demyelination, with no associated lymphocyte infiltration. The
mice received diets either deficient of (,50 IU/kg), or supplemented with low (500 IU/kg), high (6200 IU/kg) or very high
(12500 IU/kg) amounts of vit D3. Cuprizone (0.2%) was added to the diet for six weeks, starting two weeks after onset of the
experimental diets. Mouse brain tissue was histopathologically evaluated for myelin and oligodendrocyte loss, microglia/
macrophage activation, and lymphocyte infiltration after six weeks of cuprizone exposure, and two weeks after
discontinuation of cuprizone exposure. High and very high doses of vitamin D3 significantly reduced the extent of white
matter demyelination (p=0.004) and attenuated microglia activation (p=0.001). No differences in the density of
oligodendrocytes were observed between the diet groups. Two weeks after discontinuation of cuprizone exposure,
remyelination was only detectable in the white matter of mice receiving diets deficient of or with low vitamin D3 content. In
conclusion, high dietary doses of vitamin D3 reduce the extent of demyelination, and attenuate microglia activation and
macrophage infiltration in a toxic model of demyelination, independent of lymphocyte infiltration.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the central nervous system (CNS), affecting mainly
young adults. The prevalence of MS is increasing; it seems to be
caused by a complex interplay between environmental and genetic
risk factors in susceptible individuals [1,2]. Vitamin D3 (cholecal-
ciferol, vit. D3) is suggested as an environmental factor with disease
modifying functions [3,4]. Longitudinal epidemiological studies
have shown an increased risk of MS in persons with low s-vitamin
D3 levels [5–8], and low dietary intake and less sunlight exposure
are associated with an increased risk of the disease [8–12]. Low
serum levels of vitamin D3 has been found in relation to MS
relapses [13], and high serum levels of vitamin D3 in MS-patients
seem to reduce the hazard ratio for new relapses in a linear
relationship [14].
In experimental autoimmune encephalomyelitis (EAE), a T-cell
dependent animal model for MS, the activated form of vitamin
D3, 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) is highly efficient in
both disease prevention and treatment [15]. The clinical effects of
vitamin D3 are mediated via the vitamin D receptor (VDR), which
is widely distributed both on T-lymphocytes and in the CNS. The
VDR may be upregulated in activated and 1,25(OH)2D3
stimulated T-cells [16]. 1,25(OH)2-Vit D3 stimulation inhibits
transcription and secretion of pro-inflammatory cytokines, and
skews CD4+ T-lymphocytes toward a Th2 cytokine profile
[17,18].
The mechanisms for how vitamin D influences disease risk and
disease progression are, however, poorly understood. Vitamin D
status is also hypothesized to influence the risk and progression of
other, neurodegenerative disorders like Parkinsons disease [19–21]
and Alzheimers disease [19,22], in addition to schizophrenia [23,24].
This suggests that vitamin D has a role in the development and
function of the CNS beyond a modulation of T cell functions [25].
In the CNS of healthy individuals, VDR is expressed in both
neuronal- and glial cells of the gray matter, but scarcely in the white
matter [26]. In addition, the enzyme converting vitamin D3 into its
biologically active form, 1,25(OH)2 D3,1 a-hydroxylase, is widely
expressed in neuronal and glial cells in the human CNS [26–28].
The cuprizone model of de- and remyelination is a non T-cell
dependent model of toxic de- and remyelination [29,30]. The
copper chelator cuprizone induces selective oligodendrocyte
death, followed by myelin disruption, astrogliosis and microglia-
and macrophage activation. The model allows investigation of the
effects of vitamin D3 on oligodendrocyte/myelin loss and
regeneration independent of a modulation of T lymphocyte
functions.
In this study we investigated the effect of the precursor form,
unhydroxylated vitamin D3, the form physiologically provided by
dietary intake or UVB exposure in humans. We aimed to
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oligodendrocyte loss, demyelination and remyelination in the
cuprizone model for MS.
Materials and Methods
Mice
72 five-week-old female C57Bl/6 mice (Tacomic, Tornbjerg,
Denmark), with a mean weight of 20.4 g61.1 g were used for the
experiment. They were housed six together in Macrolon IVC-II
cages (Scanbur, Karlslunde, Denmark) in standard laboratory
conditions; light/dark cycles of 12/12 hours, cage temperature of
22.561uC, relative humidity of 5265% and 75 air changes per
hour. Cage maintenance was performed once weekly, and the
animals were handled by the same individuals at all times. The
animals were weighed twice weekly. The experiment was
conducted in strict accordance with the Federation of European
Laboratory Animal Science Associations recommendations, and
the protocol was approved by the Norwegian Animal Research
Authority (permit #2009-1767).
Vitamin D3 diets
Four diets, only differing in the content of vitamin D3 were
custom made by a commercial manufacturer (Altromin GmbH,
Lage, Germany). The vitamin D3 content was 1) ,50 IU/kg (e.g.
deficient), 2) 500 IU/kg, 3) 6200 IU/kg and 4) 12500 IU/kg,
respectively. The content was verified by HPLC in an independent
laboratory (Norwegian Institute for Nutrition and Seafood
Research, Bergen, Norway). The different vitamin D3 doses were
chosen to reflect relevant human dietary doses, ranging from
deficiency to the doses used in intervention studies in MS.
Assuming a daily intake of 5 g of chow per mouse per day,
allometric conversion as described earlier [31] gives estimated
human equivalent doses of 1) ,76 IU/day, 2) 760 IU/day, 3)
9425 IU/day and 4) 19003 IU/day for the different diets.
Experimental groups and cuprizone administration
After one week acclimatization, the mice (n=72) were
randomised to one of the four experimental diets. Two weeks
after randomisation, when the mice were eight weeks of age, 2/3
of the animals in each diet group (n=12) were randomised to
cuprizone exposure, while the remaining six animals in each diet
group served as healthy controls. To induce demyelination,
cuprizone (bis-cyclohexanone-oxaldihydrazone, Sigma-Aldrich,
St. Louis, MO, USA) 0.2% (w/w) was added to the milled mouse
chow. The mice had ad libitum access to chow and tap water
during the whole experimental period.
S-25(OH)-vitamin D3 and s-calcium analysis
Serum was collected at four time points during the study: 1)
before randomisation to the experimental diets, 2) After the two-
week wash-in period, before cuprizone exposure, 3) after six weeks
of cuprizone exposure, and 4) after two weeks recovery after ending
cuprizone exposure.The 25(OH)-vitamin D3 analysis was per-
formed according to a modified version of a method described
previously [32]. Briefly, 25 ml serum samples were spiked with
26,27-dexadeuterium-25-OH-Vitamin D3 (Synthetica AS, Oslo,
Norway) as internal standard and extracted with methanol and n-
hexane. The n-hexane phase was collected, evaporated to dryness
and ejected into a reverse-phase high performance liquid chroma-
tography system. Elution of 25-OH-vit D3 was performed with
methanol/water (88:12, v/v, with 0.1% formic acid) and the eluate
was monitored by a LC/MS-detector (LC/MSD SL, Agilent
Technology INC, CA 95051, USA) equipped with a multimode
ion-source. 25(OH)-vit. D3 and internal standard were monitored at
395.0and 407.3 m/z, respectively, inthe APCIpositivemode. The
mean recovery of25(OH)-vitaminD3 was77.2%(SD3.9%) andthe
interassay variation was 4.9%, with a detection limit ,4 nmol/l.
Serum calcium was analysed using Calsium AS FS (DiaSys
Diagnostic Systems GmbH, Holtzheim, Germany) [33].
Histopathology
Mice were asphyxiated with CO2, the brains removed and
fixated in 4% paraformaldehyde for at least 7 days, then paraffin
embedded. All analyses were performed on 7 mm sections 61m m
from the bregma [34]. Sections were stained with Luxol Fast Blue
(LFB) and hematoxyline and eosine (HE). For immunohistochem-
istry, the sections were dewaxed and rehydrated before antigen
retrieval in either citrate buffer (pH 6.2) or Tris-EDTA buffer
(pH 9.1). Primary antibodies and their incubation times and
temperatures are given in Table 1. Sections were blocked with
peroxidase blocking solution (Dako, Glostrup, Denmark), and
visualized with EnVision 3.3 - diaminobenzidine (1:50; 10 min at
room temperature (RT); (Dako, Glostrup, Denmark). The tissue
sections were counterstained with hematoxylin. For each antibody,
omission of the primary antibody served as negative control.
Appropriate positive controls were included in each staining
procedure. For proteolipid protein (PLP), Neurite outgrowth
inhibitor A (NOGO-A), and Mac-3, normal brain tissue from the
healthy controls served as positive controls. For the T-lymphocyte
marker CD3, sections from tonsils served as positive controls.
Characterisation of brain tissue
All sections were evaluated by two blinded observers, using light
microscopy (Leica DMLe, Wetzlar, Germany). For quantification
Table 1. Antibodies used for immunohistochemistry.
Target antigen
Species/
isotype
Working
dilution
Incubation time/
Temperature
Antigen
demasking* Source
Proteolipid Protein (PLP) Mouse IgG2a 1:1000 24 h/4uC Citrate Serotec, Oxford (UK)
Neurite Outgrowth Inhibitor Protein A
(NOGO-A)
Rabbit
polyclonal
1:1000 1 h/RT Citrate Chemicon, Temecula (CA), USA
MAC-3 Rat IgG1, K 1:200 24 h/4uC Citrate BD Biosciences, Franklin Lakes (NJ),
USA
CD3 Rabbit
polyclonal
1:4000 1 h/RT Tris-EDTA Sigma-Aldrich, St. Louis (MO), USA
RT=room temperature.
*Demasking by boiling (micorowaving) sections in the respective buffer for 15 min.
doi:10.1371/journal.pone.0026262.t001
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semiquantitatively for myelin loss in the midline of corpus
callosum using a scale ranging from 0 (complete loss of myelin)
to 3 (complete myelination), as described by Lindner and
colleagues [35]. In tissue sections immunostained for PLP, the
midline of the corpus callosum was photographed with identical
exposure settings at 406 magnification (Leica DMLe with Leica
DC300 camera). Greyscale images were thresholded in order to
avoid quantitative registration of low-intensity background
staining. The area of PLP immunopositivity in each image was
determined using Image processing and analysis in Java (U. S.
National Institutes of Health; Bethesda 2009), and expressed as the
percentage of pixels, or relative area, in each image with an
intensity within the threshold values. The number of oligoden-
drocytes (NOGO-A immunopositive cells) [36], microglia, mac-
rophages (Mac-3 immunopositive cells), and T-lymphocytes (CD3-
positive cells) was counted in an area of 0,0625 mm
2 in the midline
of the corpus callosum [34], using an ocular morphometric grid.
Statistical methods
One-way analysis of variance (ANOVA) was used to analyse
diet effects. Fishers’ least significant difference method was used as
post hoc analysis where applicable. Six cuprizone exposed mice
and 6 control mice were included in the data analysis for each diet
group. All data are presented as arithmetic mean +/21 standard
deviation. Statistical analyses were performed using PASW
Statistics 18.0 (IBM; Chicago, 2010).
Results
The dietary vitamin D3 content is reflected in serum
The analysis of the vitamin D3 metabolite 25-OH-D3 in serum
samples obtained at different time points during the study revealed
that the vitamin D3 content in the diet was reflected in the serum of
the mice (Figure 1). Prior to the experimental period, all animals
werefed a standard rodent diet (Rat and mouse No. I0 maintenance
diet from Scanbur, Special Diets Services, Karlslunde, Denmark),
containing 900 IU/kg of vitamin D3. The mean baseline s-25-OH-
vit. D3 level was 54.564.2 nmol/L. After two weeks on the
experimental diet, the serum levels raised or fell significantly in
accordance with the vitamin D3 content in the diet (p,0.0005).
There were no significant differences in the 25-OH-D3 serum levels
between the cuprizone-exposed mice and control mice (p=0.732).
An increase in serum calcium was observed in all mice during the
study period, less in the cuprizone exposed mice than in the controls
(p=0.001). There was no difference in the calcium levels of
cuprizone exposed mice between the different diet groups (Figure
S1). There was no significant difference between the diet groups
with regards to baseline body weight or weight changes (Figure S2).
High content of vitamin D3 in the diet reduces
demyelination
Significant myelin loss was observed in the corpus callosum after
six weeks of cuprizone exposure in all diet groups compared to the
control mice (p,0.0005). There were no differences in myelin
status between the control mice in the different diet groups. The
two cuprizone-exposed groups receiving the highest vitamin D3
content, 6200 and 12500 IU/kg, had significantly less demyelin-
ation in the corpus callosum than the groups receiving ,50 or
500 IU/kg (p=0.004) as determined in LFB-stained sections
(Figures 2, 3). There were no differences in the extent of
demyelination between the groups receiving 6200 IU/kg and
12500 IU/kg, or between the group receiving ,50 IU/kg and
500 IU/kg. In tissue sections immunostained for PLP, a similar
pattern was observed, as the mice receiving 12500 IU/kg vitamin
D3 in the diet had significantly less myelin loss compared to the
vitamin D3 deficient diet (p=0.02).
In all diet groups, an extensive loss of NOGO-A immunopositive
cells was observed after six weeks of cuprizone exposure (Table 2).
There were no significant differences in the degree of oligodendrocyte
loss (p=0.18) between the diet groups. Two weeks after discontinu-
ation of the cuprizone exposure, the number of NOGO-A
immunopositive cells were similar to the control mice in all diet groups.
Effects on remyelination
Two weeks after discontinuation of the cuprizone exposure,
there was no significant difference in myelin status between the
Figure 1. Serum levels of the vitamin D3 metabolite 25-OH-vit. D3. After introduction of the experimental diets the serum levels of mice fed
a diet with high vit. D3 content (6200 or 12500 IU/kg) are significantly higher than in mice fed a diet containing a very low (,50 IU/kg) or low (500 IU/
kg) amounts of vit. D3 (* p,0.0005). This difference persisted throughout the study period. However, there were no significant differences between
the two high-content groups (p=0.70) or between the two low-content groups (p=0.46).
doi:10.1371/journal.pone.0026262.g001
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exposure in the different diet groups. The mice receiving a diet deficient (,50 IU/kg) or low (500 IU/kg) in vitamin D3 content are extensively
demyelinated, and the density of activated microglia and macrophages is high. The mice receiving a diet with higher vitamin D3 content (6200 or
12500 IU/kg), are significantly less demyelinated (p=0.004), and the density of activated microglia and macrophages is significantly lower (p=0.001).
All images at 406.
doi:10.1371/journal.pone.0026262.g002
Figure 3. LFB and PLP scores. A: Semiquantitative scores of sections histochemically stained for LFB. A score of 3 indicates normal or full
myelination, while a score of 0 indicates complete demyelination. Top panel represents the scores after six weeks of cuprizone exposure, bottom
panel two weeks after discontinuation of the cuprizone exposure. Bars represent mean score, error bars represents 61 SD. * p=0.004. B: Relative area
immunopositive for PLP in the midline of corpus callosum. Top panel represents the scores after six weeks of cuprizone exposure, bottom panel
two weeks after discontinuation of the cuprizone exposure. Bars represent mean score, error bars represents 61 SD. { p=0.02.
doi:10.1371/journal.pone.0026262.g003
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vitamin D3 -low (500 IU/kg) or -deficient (,50 IU/kg) diet the
myelin status, as evaluated by LFB staining, had improved. This
was however not confirmed in tissue sections stained for PLP
(Figures 3, 4).
Dietary vitamin D3 attenuates microglia activation and
macrophage infiltration
After six weeks of cuprizone exposure, microglia activation and
macrophage infiltration were observed in all diet groups
compared to the control groups, as measured by immunohisto-
chemical staining for Mac-3. However, in the groups fed a high
vitamin D3-diet (6200 or 12500 IU/kg), the number of Mac-3
immunopositive cells were significantly lower than in the groups
fed a diet deficient of vitamin D3 (,50 IU/kg), or with a low
(500 IU/kg) vitamin D3 content (p=0.001) (Table 2, Figure 2).
There were no significant differences in the Mac-3 immunopo-
sitive cell counts between the mice fed 6200 IU/kg and
12 500 IU/kg (p=0.795), or between the mice fed ,50 IU/kg
and 500 IU/kg (p=0.682). Two weeks after discontinuation of
the cuprizone treatment, there was a significant reduction in the
Mac-3 immunopositive cell density in the groups fed ,50 IU/kg
and 500 IU/kg (p=0.018 and p=0.014, respectively). A
reduction was also observed in the groups fed 6200 IU/kg and
12500 IU/kg, this reduction was not statistically significant
(p=0.054 and 0.344) (Table 2, Figure 4).
Table 2. Density of NOGO-A immunopositive mature oligodendrocytes and Mac-3 immunopositive microglia and macrophages in
the midline of corpus callosum.
NOGO-A Mac-3
Control
6 weeks
cuprizone
exposure
2 weeks after
ending cuprizone
exposure Control
6 weeks cuprizone
exposure
2 weeks after
ending cuprizone
exposure
Diet ,50 IU/kg 61.0 (11.8) 14.8 (10.0)* 71.0 (7.8) 3.2 (2.3) 249.7 (116.2) 69.6 (19.0)
500 IU/kg 57.8 (12.4) 6.0 (5.8)* 60.2 (15.9) 1.2 (1.0) 270.0 (47.9) 45.0 (20.4)
6200 IU/kg 62.3 (17.3) 16.2 (6.2)* 72.7 (9.9) 2.3 (2.3) 95.3 (85.4)** 32.2 (10.4)
12500 IU/kg 69.5 (12.0) 11.6 (8.0)* 62.3 (7.9) 2.8 (3.0) 107.1 (53.1)** 71.5 (34.6)
Cell counts are provided as mean (6 SD) number of cells per 0.0625 mm
2.
*p,0.005.
**p=0.001.
doi:10.1371/journal.pone.0026262.t002
Figure 4. Remyelination and microglia/macrophage activation in the midline of corpus callosum two weeks after discontinuation of
cuprizone exposure in the different diet groups. Only the mice given a diet containing ,50 or 500 IU/kg of vitamin D3 had an increase in LFB
semiquantitative scores compared to at the discontinuation of the cuprizone exposure (p=0.003). There is no significant difference in the mean LFB
score between the diet groups (p=0.74), or in the PLP-immunopositive area (p=0.99). Microglia/macrophage infiltration is reduced two weeks after
ending cuprizone exposure compared to after 6 weeks cuprizone exposure. The reduction in Mac-3 immunopositive cells is most evident in the
groups fed the diets with the lower (,50 or 500 IU/kg) vitamin D3 content (,50 IU/kg: p=0.018, 500 IU/kg: p=0.014). All images at 406.
doi:10.1371/journal.pone.0026262.g004
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intervention groups
The extent of T-lymphocyte infiltration in the corpus callosum
was studied by immunohistochemical staining for the pan-T-
lymphocyte marker CD3. There was no significantly increased
infiltration of CD3 immunopositive cells in the cuprizone exposed
mice compared to in the controls (data not shown). Only single
immunopositive cells contained within blood vessel walls were
observed in both groups.
Discussion
In this study, it was found that vitamin D3, provided as a dietary
supplement, protected against cuprizone-induced demyelination,
and reduced microglia and macrophage activation. After six weeks
of cuprizone exposure, mice fed a diet with a high vitamin D3
content had significantly less myelin loss in the midline of corpus
callosum as evaluated by LFB staining and PLP immunohisto-
chemistry, both validated markers of myelin status [35]. The
results were in line with the results of epidemiological studies that
have reported correlations between high vitamin D levels and a
reduced risk of MS [5,6] and as well as reduced relapse activity
among MS patients [14].
Previous studies of the effects of vitamin D3 and 1,25(OH)2D3 in
demyelinating animal models have focussed mainly on the
inflammatory, T-cell driven EAE. Our results suggest that vitamin
D3 also has myelin-protective effects independent of T-lymphocyte
activation and infiltration. We hypothesise that the reduced degree
of demyelination observed in the groups receiving the highest
doses of vitamin D3 supplements could be due to reduced
microglia activation and macrophage infiltration.
High vitamin D3 content in the diet was significantly associated
with attenuated white matter microglia-activation/macrophage
infiltration during oligodendrocyte death and demyelination. It
has been demonstrated that the active metabolite 1,25(OH)2D3
has immunomodulatory effects by inhibiting differentiation of
dendritic cells, and de-sensitize them to maturing stimuli [37].
Macrophages and monocytes express both the vitamin D receptor
(VDR) and 1a-hydroxylase, and VDR is upregulated by
1,25(OH)2D3 stimulation in vitro [16,27]. In addition, the enzyme
24-hydroxylase, which degrades 1,25(OH)2D3 is downregulated in
activated macrophages [38,39]. No direct effects of un-hydroxyl-
ated vitamin D3 on macrophage and microglia activation and
maturation have been demonstrated previously, but the present
results suggest that the myelin protective effect of vitamin D is
dependent of a modulation of macrophage/microglial function.
No difference in the degree of oligodendrocyte loss was detected
after 6 weeks of cuprizone exposure. In the cuprizone model, signs
of oligodendrocyte death can be observed as early as after one
week of cuprizone exposure [40]. Differences in the survival time
of the oligodendrocytes could explain the observed discrepancy
between an equal loss of oligodendrocytes but different degree of
demyelination observed after six weeks of cuprizone exposure. It is
possible that diets with a low/deficient vitamin D3 content induced
a rapid and extensive loss of oligodendrocytes in cuprizone-
exposed mice, while diets with a high/very high vitamin D3
content may have induced oligodendrocyte death only after
several weeks of cuprizone exposure. In further studies, examining
the differences in oligodendrocyte density after two or three weeks
of cuprizone exposure would address this question.
The serum 25-OH-D3 levels of mice fed diets with a high- or
very high content of vitamin D3 increased during the whole study
period of 10 weeks. The serum levels reflected the .10-fold
difference in vitamin D3 content between the two low-dose and the
two high-dose diets, but did not reflect the 2-fold difference
between the two low-dose and between the two high-dose diets.
Between these high dose or low dose treatment groups no
differences were detected for any of the outcome parameters. This
could be due to that cuprizone exposure was initiated before
serum vitamin D3 levels were saturated. The serum profile
indicates that 10 weeks may not be sufficient time to achieve
saturated serum levels of 25-OH-D3, and preferably the pre-
treatment period prior to cuprizone exposure should have been
longer. However, the sensitivity of C57Bl/6 mice to cuprizone
wanes with increasing age [41], limiting the time period available
for pre-treatment.
The results could theoretically be influenced by an interaction
between cuprizone and vitamin D3, affecting the uptake and
action of either cuprizone or vitamin D3. However, the serum 25-
OH-vit D3 levels of the mice did not support this, making an effect
on vitamin D3 absorption less likely. Apart from the vitamin D3
content, the diets did not differ with regards to any other
constituents.
To our knowledge, this is the first study to investigate the
potentially myelin-protective effects of vitamin D3 in the cuprizone
model. We have previously shown that a salmon based diet with
high v-3 polyunsaturated fatty acids (PUFA) levels proved superior
to a cod liver oil based diet, with higher levels of both v-3 PUFAs
and vitamin D3 [42,43] This may suggest a complex interplay
between the dietary constituents.
A high dietary vitamin D3 content did not improve the degree
or rate of remyelination, as evaluated by LFB or PLP staining.
Two weeks after ending cuprizone exposure, remyelination was
only observed in low/deficient vitamin D3 content diet groups.
These groups were extensively demyelinated at the end of
cuprizone exposure. This may be due to a higher sensitivity of
detecting remyelination in tissue completely or completely
demyelinated at earlier time points. Further, the attenuated
microglia activation and macrophage infiltration observed in the
mice fed a diet with high vitamin D content could influence the
degree of remyelination. Microglia activation is a physiological
response to CNS injury, facilitating repair mechanisms [44].
Activated microglia and macrophages release growth factors and
inflammatory cytokines with a neurotrophic effect, stimulating
migration and differentiation of oligodendrocyte precursor cells
[45]. Significant remyelination was detected in LFB-stained tissue
sections, indicating a high sensitivity of LFB for the detection of
partial changes in myelin density. This is supported by the
sensitivity of LFB for the detection of partial demyelination in
diffuse white matter changes in MS [46].
Modulatory effects on EAE by vitamin D3 has only been shown
in female mice with intact ovaries, indicating an important
correlation between the regulation of vitamin D and oestrogen – a
correlation which is well known in humans [47–51]. In our study,
only female mice were used. It would be of interest to study the
effect of gender on thepresent results, however, cuprizone
exposure has been shown to disrupt the oestrous cycle [52], thus
making studies on gender differences less reliable.
The effect of 1,25 (OH)2 – Vit D3 in EAE has been shown to be
associated with a rise in serum calcium levels [53]. In this study,
the dietary calsium content was similar in all diets, and no
difference in the serum calcium levels was detected between the
diet groups. This suggests that the effect of vitamin D3 in the
cuprizone model is not dependent on elevation of calcium levels.
In conclusion, vitamin D3 provided as a dietary supplement
attenuate demyelination and microglia activation/macrophage
infiltration in a model of demyelination, independent of CNS
leukocyte infiltration.
Vit. D3 Reduce Cuprizone-Induced Demyelination
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Figure S1 Serum calcium levels at different time points
of the study. Left panel: s-Ca by diet. 2 weeks after ending
cuprizone exposure, a significant increase in s-Ca levels is observed
(**p,0.0005), but not during the cuprizone exposure period. No
difference in s-Ca levels are observed between the different diet
groups at any time point. Right panel: s-Ca in cuprizone
exposed mice vs controls. After 6 weeks cuprizone exposure, the
cuprizone exposed mice has significantly lower s-Ca serum levels
than in controls (* p=0.001). Error bars represent 1 SD.
(TIF)
Figure S2 Weight development during the experimental
period. Cuprizone exposed mice experienced weight loss
compared to the animals in control groups. No differences
between the diet groups were detected; neither for cuprizone
exposed nor control animals. The control animals are pooled in
one group. Error bars represent 1 SD.
(TIF)
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